GlassScriptPhysician profile
Megan A Morava
NPI 1871258756
$4,841.65
in general payments reported to CMS, 2019-2025
43 companies · $47.17 in 2025
The $47.17 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $3,143 · 2023: $1,119 · 2024: $246 · 2025: $47.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $814.35 | 2021-2025 | |
| Taiho Oncology, INC. | $396.67 | 2022-2023 | |
| Incyte Corporation | $351.88 | 2022-2023 | Jakafi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $317.84 | 2021-2023 | |
| Seagen INC. | $294.91 | 2022-2023 | Tukysa |
| Genzyme Corporation | $258.44 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $239.74 | 2021-2023 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $172.07 | 2021-2023 | Imbruvica, Darzalex |
| Pharmacosmos Therapeutics INC. | $127.35 | 2022 | |
| Eisai INC. | $110.97 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $110.47 | 2023 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $109.73 | 2022-2023 | Alunbrig |
| Daiichi Sankyo INC. | $104.37 | 2022 | |
| Beigene USA, INC. | $98.47 | 2022-2023 | Brukinsa |
| Kyowa Kirin, INC. | $94.01 | 2022-2023 | Poteligeo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Morava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.